A
AnaptysBio D
D
ANAB
20.430
USD
-0.26
(-1.26%)
مغلق
حجم التداول
18,636
الربح لكل سهم
-5
العائد الربحي
-
P/E
-4
حجم السوق
600,243,533
الأخبار المقالات
العنوان: AnaptysBio
القطاع: Healthcare
الصناعة: Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).